MedPath

Renal Sympathetic Denervation after Renal Transplantation Study - I

Phase 4
Withdrawn
Conditions
Hypertension
10057166
Registration Number
NL-OMON37506
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

Hypertension despite 2 or more anti-hypertensive drugs
Functioning transplant kidney in situ

Exclusion Criteria

Renal artery stenosis of native of transplant reanl arteries
Primary hyperaldosteronisme

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Procedural success (4-8 ablation per renal artery) without adverse events<br /><br>during hospitalization (death, renal artery dissection, renal or peripheral<br /><br>embolisation, major bleeding).<br /><br>Blood pressure reduction at 6 months, by 24-h RR measurement.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Efficacy endpoints: clinical cardiovascular events, systemic and imaging<br /><br>parameters of left ventricular remodelling, laboratory parameters of<br /><br>sympathetic and RAAS activation, laboratory assessment of parameters of<br /><br>cardiovascular fibrosis and gene expression of cardiovascular fibrosis</p><br>
© Copyright 2025. All Rights Reserved by MedPath